Aclaris Therapeutics, Inc.
Income Statement
| Line Item | FY2017 |
|---|---|
| Revenue | $1.7M |
| Cost of Revenue | $1.2M |
| Gross Profit | $476.0K |
| Gross Margin | 28.3% |
| Operating Expenses | |
| Research & Development | $35.8M |
| SG&A Expense | $18.9M |
| Operating Income | $-54.4M |
| Operating Margin | -3,230.0% |
| Interest Expense | — |
| Pretax Income | $-70.4M |
| Income Tax Expense | $-1.8M |
| Net Income | $-68.5M |
| Net Margin | -4,071.5% |
| EPS (Basic) | $-2.44 |
| EPS (Diluted) | $-2.44 |
| Shares Outstanding (Basic) | 30.9M |
| Shares Outstanding (Diluted) | 30.9M |
| Dividends Per Share | — |